Biomarker Core

生物标志物核心

• 批准号: 10666448
• 负责人: LEE-WAY JIN
• 金额: $ 32.37万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10666448
• 关键词: Alzheimer' s Disease; Alzheimer' s disease pathology; Amyloid; Amyloid beta-Protein; Bar Codes; Biological; Biological Markers; Blood; Blood specimen; Brain Injuries; Categories; Clinical; Clinical Trials; Cognitive; Cognitive aging; Collaborations; Collection; Communities; Complex; Computer software; DNA; Data; Databases; Dementia; Deposition; Diagnostic; Disease; Elderly; Epidemiology; Equipment and supply inventories; Faculty; Freezing; Funding; Genetic; Goals; Grant; Heterogeneity; Impaired cognition; Individual; Infrastructure; Intervention; Life; Longitudinal cohort; Mentors; Outcome; Pathologic Processes; Pathology; Phenotype; Plasma; Population Heterogeneity; Procedures; Process; Qualifying; RNA; Race; Regulation; Research; Research Personnel; Resources; Retrieval; Sampling; Secure; Serum; Specimen; Standardization; Study Subject; System; Technology; Time; Validation; Work; accurate diagnosis; biobank; biomarker discovery; blood-based biomarker; career development; clinical epidemiology; cohort; cost efficient; data sharing; epidemiology study; frontier; glycoproteomics; indexing; innovation; lipidomics; metabolomics; multi-ethnic; multiple omics; neuroimaging; neuropathology; novel marker; operation; programs; protein biomarkers; repository; research and development; response; risk prediction model; saliva sample; sample collection; specific biomarkers; standardize measure; tau Proteins; tau-1; tool; web based interface; web portal

PROJECT SUMMARY – Biomarker Core The overarching goal of the UCD ADRC is to understand the multiple and complex determinants that explain heterogeneity of cognitive trajectories and progression to dementia among a cohort of diverse older adults. In line with this goal, our study subjects form a diverse multi-ethnic/racial longitudinal cohort. To be able to offer disease-modifying interventions in the subject’s lifetime, a precise and dynamic biological definition of the subject’s disease trajectory is essential. It requires a comprehensive biomarker assessment of both AD pathology and non-AD specific brain injury that may contribute to and modify the trajectories of cognitive decline. This task is particularly critical when faced with mixed pathological processes manifested by subjects of diverse backgrounds. To meet this challenge, the UC Davis ADRC launched a biorepository in 2014 to collect blood specimens and establish standard operation procedures. We have since grown substantially in expertise and sample collection via continuous funding through several NIA- and Alzheimer’s Association- funded blood biomarker, clinical trial, and epidemiological projects, as well as participation in national programs such as MarkVCID, ADNI, NCRAD, and AD Metabolomic Consortium. Currently we have deposited thousands of blood specimens (serum, plasma, DNA, and RNA) from 1279 subjects in our ADRC Longitudinal Cohort; hundreds of them have given longitudinal samples. We have also collected saliva and blood samples from hundreds of subjects participating in ADRC-affiliated clinical trials and epidemiological projects such as the Life After 90 Study. Sample categorization, inventory, tracking, and retrieval are conducted by the barcode-based OpenSpecimen network software, which is further integrated into the ADRC Web-based interface. Moreover, we have established expertise in ultra-sensitive protein biomarker analysis using SiMoA technology, and built a broad multi-omics platform for collaboration by providing expertise and resources for emerging omics technology including glycomics, glycoproteomics, lipidomics, and metabolomics. In this ADRC application, we will formally establish the Biomarker Core (BC), which will accomplish the following four specific aims: Aim 1 – to expand the repository of high-quality samples from diverse populations; Aim 2 – to quantify and integrate essential and emerging blood biomarkers to support diagnostics and theragnostics efforts of ADRC; Aim 3 – to provide infrastructure to support novel biomarker discovery, clinical trials, and UCD ADRC-affiliated clinical and epidemiological projects; and Aim 4 – to extend our existing robust and cost-efficient systems for sharing data and specimens broadly with the research community to support innovative research and career development. We believe the deposited data and specimens from our diverse multi-ethnic/racial longitudinal cohort will constitute a unique, readily sharable resource to enable cognitive stage-dependent analyses of inter-related biomarkers in data- and hypothesis-driven studies. Our expertise in SiMoA, glycomics, lipidomics, and metabolomics will help investigators nationwide to advance into new frontiers of biomarker discovery.

项目摘要 - 生物标志物核心 UCD ADRC的总体目标是理解多重和复杂的确定解释 认知轨迹的异质性和对痴呆症的痴呆症的异质性。 与这个目标保持一致，我们的研究对象构成了潜水员的多种族/种族纵向人群。能够提供 对受试者一生的疾病改良干预措施，对 受试者的疾病轨迹至关重要。它需要对两个广告进行全面的生物标志物评估 病理和非AD特异性脑损伤可能有助于并改变认知的轨迹 衰退。当面对受试者表现出的混合病理过程时，此任务尤其重要 潜水员背景。为了应对这一挑战，加州大学戴维斯分校ADRC在2014年推出了一个生物座席 收集血样并建立标准操作程序。从那以后，我们已经大大发展了 通过连续资金通过几个NIA和阿尔茨海默氏症协会进行专业知识和样本收集 - 资助的血液生物标志物，临床试验和流行病学项目以及参与国家计划 例如MarkVcID，ADNI，NCRAD和AD代谢集团。目前我们已经存入了数千人 来自ADRC纵向队列中1279名受试者的血液标本（血清，血浆，DNA和RNA）的血液标本； 其中数百个给出了纵向样本。我们还从 数百名参与ADRC相关临床试验和流行病学项目的受试者，例如生活 经过90研究。样本类别，库存，跟踪和检索由条形码进行 OpenSpececimen网络软件，该软件进一步集成到基于ADRC Web的接口中。而且， 我们已经使用Simoa技术建立了超敏感蛋白质生物标志物分析的专业知识，并建立了一个 通过为新兴的OMIC提供专业知识和资源，用于合作的广泛多摩斯 包括糖蛋白质组学，脂质组学和代谢组学在内的技术。在此ADRC应用程序中，我们 将正式建立生物标志物核心（BC），该核心将实现以下四个特定目标：AIM 1 - 扩大来自潜水员人群的高质量样本的存储库；目标2 - 量化和整合 必不可少的和新兴的血液生物标志物支持ADRC的诊断和热力学工作；目标3 - 提供基础设施来支持新型的生物标志物发现，临床试验和UCD ADRC相关的临床和 流行病学项目；目标4 - 扩展我们现有的可靠和成本效益的系统来共享数据 并广泛地与研究界的标本来支持创新的研究和职业发展。 我们认为，来自我们潜水员的多种族/种族纵向队列的存入数据和标本将会 构成独特的，易于共享的资源，以实现相互关联的认知阶段依赖性分析 数据和假设驱动的研究中的生物标志物。我们在SIMOA，糖基质，脂肪态学和 代谢组学将帮助全国的调查人员进入生物标志物发现的新领域。